Nexalin Technology, Inc. (NXL) Research

Nexalin Technology, Inc. operates as a medical device firm specializing in the creation and advancement of neurostimulation therapies for mental health conditions in both the United States and China. The company commercializes its primary product, the Nexalin Device, which provides a non-invasive and drug-free treatment for anxiety and insomnia. This device functions by emitting a proprietary frequency-based waveform designed to elicit a beneficial response from mid-brain structures associated with various psychological disorders. Furthermore, Nexalin Technology is currently developing "Generation 2," a new medical device undergoing clinical trials. This future product aims to address a broader spectrum of health issues, including opiate addiction, persistent pain, Alzheimer's disease, and dementia. The company was founded in 2021 and has its headquarters in Houston, Texas.

Market snapshot

Symbol
NXL
Price
$0.37
Day change
-6.36%
Market cap
$7.6M
P/E ratio
-0.88x
52-week range
0.305-2
Sector
Healthcare
Industry
Medical - Devices
Next earnings
in 2 months

Peer companies

  • CollPlant Biotechnologies Ltd. (CLGN)
  • Enlivex Therapeutics Ltd. (ENLV)
  • Harvard Bioscience, Inc. (HBIO)
  • Inspira Technologies Oxy B.H.N. Ltd. (IINN)
  • Modular Medical, Inc. (MODD)
  • NeurAxis, Inc. (NRXS)
  • Vicarious Surgical Inc. (RBOT)
  • Retractable Technologies, Inc. (RVP)

Recent insider activity

  • White Mark — A-Award (1000000 shares) on 2025-12-19
  • Van Fleet Justin — A-Award (100000 shares) on 2025-12-19
  • Owens David — A-Award (1000000 shares) on 2025-12-19
  • Shelton Carolyn Hamby — A-Award (100000 shares) on 2025-12-19
  • Hu Ben — A-Award (100000 shares) on 2025-12-19

Open Nexalin Technology, Inc. (NXL) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.